ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
P/B ratio for ImmunoGen, Inc. (IMGN)
P/B ratio as of 2022: 8.07
According to ImmunoGen, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.07. At the end of 2021 the company had a P/B ratio of 12.08.
P/B ratio history for ImmunoGen, Inc. from 1988 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 8.07 |
| 2021 | 12.08 |
| 2020 | 12.68 |
| 2019 | -9.96 |
| 2018 | 56.25 |
| 2017 | -35.13 |
| 2016 | -1.16 |
| 2015 | -3.30 |
| 2014 | 35.24 |
| 2013 | 13.38 |
| 2012 | 11.86 |
| 2011 | 15.33 |
| 2010 | 6.00 |
| 2009 | 5.35 |
| 2008 | 6.58 |
| 2007 | 2.38 |
| 2006 | 3.97 |
| 2005 | 1.78 |
| 2004 | 2.72 |
| 2003 | 2.54 |
| 2002 | 1.74 |
| 2001 | 0.70 |
| 2000 | 5.15 |
| 1999 | 23.17 |
| 1998 | 11.13 |
| 1997 | 9.85 |
| 1996 | 6.19 |
| 1995 | 19.68 |
| 1994 | 4.83 |
| 1993 | 1.61 |
| 1992 | 1.70 |
| 1991 | 2.01 |
| 1990 | 2.09 |
| 1989 | 5.82 |
| 1988 | 2.14 |